Forest Ray PhD,  —

Novus Therapeutics has enrolled the first patient in its Phase 2a trial of AT-1501 in adults with amyotrophic lateral sclerosis (ALS), the company announced in a press release. The trial is enrolling up to 54 adults with ALS across up to 12 U.S. treatment sites. Currently,…

Catalent Biologics has agreed to manufacture NurOwn, the cell-based therapy by BrainStorm Cell Therapeutics being evaluated in a soon-to-conclude pivotal trial as a possible treatment of amyotrophic lateral sclerosis (ALS). With this agreement, Catalent will produce NurOwn under current Good Manufacturing Practices — standards set to ensure that batches…

A metabolite of testosterone, dihydrotestosterone (DHT), is found at significantly lower levels in the cerebrospinal fluid of people with amyotrophic lateral sclerosis (ALS), a small study found. This metabolite, or hormone, is likely critical for the survival of motor neurons, and its lack in the central…

A Phase 2 and potentially pivotal study investigating pegcetacoplan (APL-2) as a potential treatment for amyotrophic lateral sclerosis (ALS) is now enrolling patients, Apellis Pharmaceuticals, the therapy’s developer, announced in a press release. The MERIDIAN trial (NCT04579666) is enrolling up to 228 adults with sporadic ALS and…

Three grants given researchers at two centers in Australia will advance work into ways of preserving nerve cells in people with amyotrophic lateral sclerosis (ALS), and other motor neuron diseases. The grants, totaling AU$1.5 million (about $1.1 million), came from FightMND, an Australian nonprofit patient advocacy group. Lezanne…

Novus Therapeutics has acquired Anelixis Therapeutics and its portfolio, including the antibody AT-1501, a potential treatment for amyotrophic lateral sclerosis (ALS) that the company is planning to move into a Phase 2 clinical trial for ALS and other diseases. AT-1501 is an antibody against a…

IPL344, Immunity Pharma‘s investigational therapy for amyotrophic lateral sclerosis (ALS), has a positive safety and tolerability profile and slows disease progression by about 50%, according to interim results from a small Phase 1/2a clinical trial. The company said it now is planning a placebo-controlled trial to evaluate IPL344…

Helixmith has selected Worldwide Clinical Trials to run a planned Phase 2 study of Engensis (VM202), its potential gene therapy for amyotrophic lateral sclerosis (ALS), according to a company press release. Engensis consists of a circular piece of DNA called a plasmid that carries instructions…

Patient enrollment is now complete for the Phase 2 clinical trial of Clene Nanomedicine‘s CNM-Au8 as a potentially disease-modifying therapy for amyotrophic lateral sclerosis (ALS). The trial, named RESCUE-ALS (NCT04098406) will test the safety, efficacy, pharmacokinetics, and pharmacodynamics —…

Younger cycad seeds can contain more toxins than older seeds, and their widespread consumption by people on occupied Guam during World War II could be the environmental origin of the rare sporadic amyotrophic lateral sclerosis (ALS) cluster found there, according to a recent study. Guam residents emerged from their wartime…